Plant Name: Allium macrostemon
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ADORA3; ADORA2A; ADORA1; HTR6; | |
| RECQL; TDP1; MIF; MTOR; ADK; TERT; HPGD; ALDH1A1; | |
| TRPA1; | |
| CDK2; GSK3B; CDK1; | |
| MT-ND4; | |
| CTSB; CTSL; | |
| AHR; TP53; STAT6; | |
| SLC28A1; SLC28A3; SLC28A2; | |
| LMNA; MAPT; PMP22; GMNN; RAB9A; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CTSB | Cathepsin B | P07858 | CHEMBL4072 |
| Cysteine protease | CTSL | Cathepsin L | P07711 | CHEMBL3837 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Oxidoreductase | MT-ND4 | NADH-ubiquinone oxidoreductase chain 4 | P03905 | CHEMBL4499 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | CDK2 | Cyclin-dependent kinase 2 | P24941 | CHEMBL301 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | PMP22 | Peripheral myelin protein 22 | Q01453 | CHEMBL1293298 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.898E-07 | 5.904E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 4.544E-07 | 1.099E-03 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 3.190E-06 | 5.343E-03 | SLC28A2, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 3.190E-06 | 5.343E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 3.190E-06 | 5.343E-03 | SLC28A2, SLC28A3 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 3.003E-06 | 5.343E-03 | ADORA1, ADORA2A, MAPT |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 6.525E-06 | 8.451E-03 | ADORA2A, AHR, CDK1, HPGD, STAT6, TP53, TRPA1 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 9.558E-06 | 8.451E-03 | SLC28A1, SLC28A3 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 9.558E-06 | 8.451E-03 | SLC28A1, SLC28A3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 9.558E-06 | 8.451E-03 | ADORA1, ADORA2A |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.113E-05 | 8.973E-03 | GSK3B, MAPT, MTOR, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.726E-05 | 1.744E-03 | GSK3B; CDK2; TP53; MTOR |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.017E-04 | 2.294E-03 | CTSL; LMNA; TP53; CTSB |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 9.094E-05 | 2.294E-03 | GSK3B; CDK2; RAB9A; TP53 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 6.351E-05 | 2.294E-03 | GSK3B; CDK2; CDK1; TP53 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.135E-04 | 2.294E-03 | HTR6; ADORA2A; ADORA3; ADORA1; TSHR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.911E-04 | 5.225E-03 | HTR6; ADORA2A; ADORA1; TSHR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 4.139E-04 | 5.225E-03 | GSK3B; CDK2; CDK1; TP53 |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 2.377E-04 | 4.000E-03 | CDK2; CDK1; TP53 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 9.820E-04 | 1.100E-02 | HTR6; CYP2D6; CYP2C19 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.142E-03 | 1.100E-02 | GSK3B; TP53; MTOR |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.865E-03 | 2.226E-02 | GSK3B; CDK2; TP53; MTOR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.198E-03 | 1.100E-02 | ADORA3; ADORA1; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.102E-03 | 1.769E-02 | CDK2; STAT6; TP53 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 4.924E-03 | 2.536E-02 | GSK3B; CDK2; TP53; MTOR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.734E-03 | 2.536E-02 | GSK3B; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 5.310E-03 | 2.536E-02 | CTSL; TP53; MTOR |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 4.100E-03 | 2.536E-02 | CDK2; CDK1; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 5.456E-03 | 2.536E-02 | CDK2; CDK1; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 4.318E-03 | 2.536E-02 | ADORA1; TSHR |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 4.168E-03 | 2.536E-02 | GSK3B; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 5.267E-03 | 2.536E-02 | GSK3B; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 5.775E-03 | 2.536E-02 | TP53; MTOR |
| hsa04924 | Renin secretion_Homo sapiens_hsa04924 | 5.603E-03 | 2.536E-02 | ADORA1; CTSB |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.024E-02 | 3.567E-02 | GSK3B; TERT; TP53 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.125E-03 | 2.578E-02 | TP53; MTOR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.485E-03 | 2.620E-02 | CYP2D6; CYP2C19 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.014E-02 | 3.567E-02 | GSK3B; MTOR |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.918E-03 | 3.567E-02 | CDK2; TP53 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.273E-02 | 4.147E-02 | CDK2; CDK1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.176E-02 | 3.958E-02 | TP53; MTOR |
| hsa04612 | Antigen processing and presentation_Homo sapiens_hsa04612 | 8.018E-03 | 3.115E-02 | CTSL; CTSB |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.558E-02 | 4.916E-02 | GSK3B; MTOR |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | CTSL |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; MAPT; HTR6 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR |
| C00-D49: Neoplasms | Cancer | C00-C96 | CDK2; GSK3B; ADORA3; TP53; MTOR; CDK1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TERT |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | CDK2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; TERT |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR6 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; MTOR; MTOR; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR6; HTR6 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CDK2; TP53; MTOR |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MTOR; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; MTOR; CDK1; ADK; TRPA1 |
| C00-D49: Neoplasms | Thymoma | C37, D15.0 | CDK2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA2A; ADORA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA2A; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR6 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MIF; MTOR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | CDK2; MTOR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR6 |
| NA: NA | HIV infections | NA | AHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; HTR6 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA2A; ADORA1 |
| C00-D49: Neoplasms | Melanoma | C43 | TERT |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | MTOR |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; TERT |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| NA: NA | Coronary artery restenosis | NA | MTOR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; MAPT; HTR6; HTR6; HTR6 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT |